Altamira Therapeutics Ltd Revenue Growth Rates (CYTO), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Altamira Therapeutics Ltd   (NASDAQ: CYTO)
 

CYTO's Revenue Growth by Quarter and Year

Altamira Therapeutics Ltd 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYTO Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December 0.00
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 0.00

CYTOs Annual Revenue
Altamira Therapeutics Ltd 's Revenue in the fiscal year 2024 $ 0.00 millions
Altamira Therapeutics Ltd 's Revenue in the fiscal year 2023 $ 0.00 millions
Altamira Therapeutics Ltd 's Revenue in the fiscal year 2022 $ 0.31 millions
Altamira Therapeutics Ltd 's Revenue in the fiscal year 2021 $ 0.07 millions
Altamira Therapeutics Ltd 's Revenue in the fiscal year 2020 $ 0.23 millions




CYTO Revenue fourth quarter 2023 Y/Y Growth Comment
Altamira Therapeutics Ltd in the fourth quarter 2023 recorded of $ 0.00 millions.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 250 other companies have achieved higher Revenue growth. While Altamira Therapeutics Ltd ' s Revenue meltdown of -100% ranks overall at the positon no. 4598 in the fourth quarter 2023.


CYTO Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Altamira Therapeutics Ltd 's fourth quarter 2023 Revenue $ 0.00 millions CYTO's Income Statement
Altamira Therapeutics Ltd 's fourth quarter 2022 Revenue $ 0.31 millions Quarterly CYTO's Income Statement


CYTO Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Back to CYTO Growth rate Comparisons >> Back to CYTO Growth rate Comparisons >>


Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #251
Healthcare Sector #655
Overall #4598

Revenue Y/Y Growth Statistics
High Average Low
337.38 % 133.61 % -70.16 %
(Dec 31 2022)   (Dec 31 2021)
Revenue fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #251
Healthcare Sector #655
Overall #4598
Revenue Y/Y Growth Statistics
High Average Low
337.38 % 133.61 % -70.16 %
(Dec 31 2022)   (Dec 31 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Altamira Therapeutics Ltd 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYTO's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYTO's IV. Quarter Q/Q Revenue Comment


Altamira Therapeutics Ltd 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Dec 31 2020)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.31 $ 0.07 $ 0.23
Y / Y Revenue Growth (TTM) - - 337.38 % -70.16 % -
Year on Year Revenue Growth Overall Ranking # 4598 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) - - 337.38 % -70.16 % -
Seq. Revenue Growth (TTM) Overall Ranking # 4598 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
In the Dec 31 2024 period, Altamira Therapeutics Ltd 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 654 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4598.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 251
Healthcare Sector # 655
Overall # 4598

Revenue TTM Y/Y Growth Statistics
High Average Low
337.38 %
 133.61 %
-70.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 251
Sector # 655
S&P 500 # 4598
Cumulative Revenue growth Comment
In the Dec 31 2024 period, Altamira Therapeutics Ltd 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

In the Healthcare sector 654 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 4598.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 251
Healthcare Sector # 655
Overall # 4598

Revenue TTM Y/Y Growth Statistics
High Average Low
337.38 %
133.61 %
-70.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 251
Sector # 655
S&P 500 # 4598




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CYTO's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2023
Healthcare Services Group Inc -0.04%$ -0.042 millions
Integra Lifesciences Holdings Corp-0.25%$ -0.247 millions
Nrc Health-0.37%$ -0.375 millions
Skinhealth Systems Inc -0.63%$ -0.633 millions
3m Company-0.82%$ -0.817 millions
Enhabit Inc -0.95%$ -0.950 millions
Viatris Inc -1.00%$ -0.998 millions
Aspira Women s Health inc -1.07%$ -1.068 millions
Supernus Pharmaceuticals inc -1.80%$ -1.801 millions
Opko Health Inc -1.85%$ -1.853 millions
Quest Diagnostics Inc-1.93%$ -1.929 millions
Koru Medical Systems Inc -2.16%$ -2.161 millions
Envista Holdings Corporation-2.30%$ -2.300 millions
Ideaya Biosciences Inc -2.46%$ -2.461 millions
Zynex inc -3.11%$ -3.114 millions
Shl Telemedicine Ltd-3.26%$ -3.259 millions
Pediatrix Medical Group Inc -3.39%$ -3.386 millions
Baxter International Inc -3.55%$ -3.550 millions
Caribou Biosciences Inc -3.63%$ -3.629 millions
Gilead Sciences Inc -3.72%$ -3.722 millions
Lifevantage Corp-3.92%$ -3.921 millions
Avantor Inc -4.02%$ -4.022 millions
Sensus Healthcare Inc -4.11%$ -4.106 millions
Outset Medical Inc -4.17%$ -4.168 millions
Journey Medical Corp-4.44%$ -4.441 millions
Escalon Medical Corp -4.53%$ -4.533 millions
Waters Corporation-4.55%$ -4.547 millions
Inovio Pharmaceuticals Inc -4.55%$ -4.553 millions
Biolase Inc -4.68%$ -4.683 millions
American Shared Hospital Services-4.73%$ -4.725 millions


About Altamira Therapeutics Ltd Revenue Growth Rates (CYTO), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Altamira Therapeutics Ltd (CIK 1601936).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001213900-25-037199
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Altamira Therapeutics Ltd ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.